The article presents insights into the diagnosis and treatment of secondary thrombotic microangiopathy (TMA) and the specific features of differential diagnosis of aHUS from other forms of TMA. Contemporary principles of aHUS management and genetic characteristics of the disease are discussed in details.

Keywords: Atypical hemolytic uremic syndrome, everolimus, thrombotic microangiopathy